Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 23, 2016 16:26:00 GMT -5
The Chief Commercial Officer is a member of this board. If Senators want to make this their "pet project" the time to be in their ear with a solution is RIGHT NOW, not 6 months down the road. Hopefully this was immediately apparent to management before I mentioned it! But not others in management. And not sure if he reads every post on this board
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 23, 2016 16:27:49 GMT -5
Another Epi Pen story in USA Today: www.usatoday.com/story/news/politics/2016/08/23/epipens-steady-price-increases-masked-until-deductibles-rose/89123786/MNKD is missing a GOLDEN OPPORTUNITY right now. There is a tremendous market need for a reasonably priced Technosphere based Epi product. Now it's become political football as well, with intolerable 600% price increases from Mylan. For once, can we strike while the iron is HOT?! Enter the public debate/discussion, partner up with a heavyweight, get political/FDA support, get free media hype, and execute for once! We have this unbelievable technology but after all these years our lack of execution is about to send us into bankruptcy. It's such a freaking waste... So MannKind should wave a magic wand and make the FDA disappear, leaving it free to put a Technosphere-based EPI on the market tomorrow, without all those pesky trials, etc. As for possible partners, how do you counter the argument that since Afrezza has so far been a flop any other use of Technosphere would flop too. Seems to me Afrezza has to redeem itself before anybody else will want to touch Technosphere. I continue to believe that eventually both Afrezza and Technosphere will be success stories, with the emphasis on eventually. How had Afrezza been a flop? Are you are referring to Sanofi, and how they were more worried about losing millions because of Lantus losing patent protection, and them launching Touejo and putting all their efforts into that? Well, they are getting their karma now. Also, Receptor Life Sciences is using Technosphere, specifically because of its superiority and vast capabilities compared to anything else. Afrezza is changing the foundation of how a chronic condition has been treated for decades. This sort of change will take time, and honestly, the results from people using Afrezza are pretty incredible. Also, we still don't know what is going on behind the scenes with TechnoVax and Mintaka. Both who think that Technosphere is the answer.
|
|
|
Post by kc on Aug 23, 2016 16:54:26 GMT -5
I continue to believe that eventually both Afrezza and Technosphere will be success stories, with the emphasis on eventually.
I hope that your 100% correct and that it occurs soon than later as it might be the next owner of MannKind's assets to see the success that we should currently have.
|
|
|
Post by kc on Aug 23, 2016 16:57:50 GMT -5
The Chief Commercial Officer is a member of this board. If Senators want to make this their "pet project" the time to be in their ear with a solution is RIGHT NOW, not 6 months down the road. Hopefully this was immediately apparent to management before I mentioned it! I think this is more in Ray Urbanski's vision than in Mike C. Interesting that Urbansk was a former Mylan employee.
|
|
|
Post by lakers on Aug 23, 2016 20:39:11 GMT -5
How EpiPen's maker raised prices, and hackles, so much www.usnews.com/news/business/articles/2016-08-23/how-epipens-maker-raised-prices-and-hackles-so-muchThe company, Mylan, has a virtual monopoly on epinephrine injectors, potentially life-saving devices used to stop a runaway allergic reaction. Mylan N.V., which has headquarters in Hertfordshire, England, and Pittsburgh, has hiked prices as frequently as three times a year over the past nine years, pushing its list price for a package of two syringes to more than $600. A look at the situation: Q: Who uses EpiPens? Roughly 40 million Americans have severe allergies to spider bites, bee stings and foods like nuts, eggs and shellfish. They at risk for a serious reaction — anaphylactic shock. Symptoms quickly escalate from wheezing, hives and skin swelling to rapid heartbeat, trouble breathing and convulsions and, without treatment, possibly death. As a precaution, many carry EpiPens, which contain the best "antidote," the hormone epinephrine. Last year, more than 3.6 million U.S. prescriptions for two-packs of EpiPens were filled, according to data firm IMS Health. That earned Mylan nearly $1.7 billion. Q: How did the price for EpiPens get so high? Like all drugmakers, Mylan periodically hikes its prices. In 2007, when Mylan took over rights to EpiPen, a pair of syringes cost $93.88. According to Elsevier Clinical Solutions' database of prices set by manufacturers, Mylan raised the price 5 percent the in 2008 and 2009, when a competitor hit the market. Its price jumped 20 percent in late 2009, followed by a series of 10 percent and 15 percent increases. The price hit $609 per pair in mid-May. Q: Isn't there any competition? A: Barely, and few people know about it. One cheaper product remains on the market, Adrenaclick. But EpiPen, introduced in 1987, is so well known that most doctors prescribe it without considering Adrenaclick, and pharmacists can't substitute that for EpiPen, said Evelyn Hermes-DeSantis, director of drug information services at Rutgers University's pharmacy school. A pair of Adrenaclick syringes costs $142 to $380 at pharmacies, according to online comparison sites. EpiPen has a U.S. patent giving it a monopoly until 2025, according to Evercore ISI analyst Umer Raffat. Generic maker Teva has permission to launch a version but hasn't gotten regulatory approval yet. A rival injector called Auvi-Q was recalled last year because of potential inaccurate dosing, Raffat noted, and a third product has twice been rejected because of issues with the injector. Q: Is there another alternative? A: Some people get prescriptions for epinephrine vials and get a doctor to put it in syringes. But Rutgers' Hermes-DeSantis said that raises concerns about sterility and proper storage.
|
|
|
Post by gamblerjag on Aug 23, 2016 21:29:34 GMT -5
Boy the below sounds familiar relating to Afrezza. Hopefully Endos will learn about Afrezz and get on the ball and not be afraid to try something better.
Q: Isn't there any competition?
A: Barely, and few people know about it. One cheaper product remains on the market, Adrenaclick. But EpiPen, introduced in 1987, is so well known that most doctors prescribe it without considering Adrenaclick,
Read more: mnkd.proboards.com/posts/recent#ixzz4IDG3Bnkm
|
|
|
Post by LosingMyBullishness on Aug 24, 2016 5:44:29 GMT -5
It is even for a long-term and patient investor difficult to comprehend why MNKD is not using media actively to their advantage in the area of Epi. Negotations in the back room are fine but that does not confine many other companies to get publicity to push up the interest and price. This is especially true if there is someone for the media to attack, like Mylan.
In the past I had the impression that ol' Mannkind was playing too much by the book of old-school honest company in a sea of sharks. Still, even with the water being red from their own blood and the sharks circling, they are understating and underperforming when it comes to gaining media interest.
I understand that getting Afrezza Sales up is first priority..but why not give one interview to see if the media picks it up?
|
|
|
Post by mnholdem on Aug 24, 2016 6:57:52 GMT -5
I agree 100%. As CEO, Matt Pfeffer cannot sit on his hands when opportunities like this arise. He needs to be getting the message out NOW about MannKind's development of TS-Epinephrine and their plan to sell it at a fraction of the price of the EpiPen if it's approved by the FDA. Press releases, talk shows, articles... MannKind really needs to become more media-savvy, IMO, and they need to do it NOW while Mylan's price-gouging is a hot topic and lawmakers are putting pressure on Mylan.
It's free publicity and a buildup of demand for TS-Epinephrine will be heard by the FDA.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 24, 2016 8:28:06 GMT -5
I agree 100%. As CEO, Matt Pfeffer cannot sit on his hands when opportunities like this arise. He needs to be getting the message out NOW about MannKind's development of TS-Epinephrine and their plan to sell it at a fraction of the price of the EpiPen if it's approved by the FDA. Press releases, talk shows, articles... MannKind really needs to become more media-savvy, IMO, and they need to do it NOW while Mylan's price-gouging is a hot topic and lawmakers are putting pressure on Mylan.
It's free publicity and a buildup of demand for TS-Epinephrine will be heard by the FDA. I sent an email to Matt. Can you too please?
|
|
|
Post by mnholdem on Aug 24, 2016 8:29:57 GMT -5
I already have.
|
|
|
Post by flatrock on Aug 24, 2016 8:48:04 GMT -5
Interesting the way the health care system gouges American consumers:
"After insurance company discounts, a package of two EpiPens costs about $415, DRX says. By comparison, in France, where Meda sells the drug, two EpiPens cost about $85."
|
|
|
Post by madog365 on Aug 24, 2016 8:50:00 GMT -5
I agree 100%. As CEO, Matt Pfeffer cannot sit on his hands when opportunities like this arise. He needs to be getting the message out NOW about MannKind's development of TS-Epinephrine and their plan to sell it at a fraction of the price of the EpiPen if it's approved by the FDA. Press releases, talk shows, articles... MannKind really needs to become more media-savvy, IMO, and they need to do it NOW while Mylan's price-gouging is a hot topic and lawmakers are putting pressure on Mylan.
It's free publicity and a buildup of demand for TS-Epinephrine will be heard by the FDA. Yes. This 100% Ray Urbanski, former CMO at Mylan is now working at Mannkind as CMO and pushing along an epipen alternative inhaled epinephrine treatment. That right there is a story media companies will pick up and run with. It will also give free publicity to Afrezza. Get this guy doing interviews right NOW.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 24, 2016 8:59:12 GMT -5
I agree 100%. As CEO, Matt Pfeffer cannot sit on his hands when opportunities like this arise. He needs to be getting the message out NOW about MannKind's development of TS-Epinephrine and their plan to sell it at a fraction of the price of the EpiPen if it's approved by the FDA. Press releases, talk shows, articles... MannKind really needs to become more media-savvy, IMO, and they need to do it NOW while Mylan's price-gouging is a hot topic and lawmakers are putting pressure on Mylan.
It's free publicity and a buildup of demand for TS-Epinephrine will be heard by the FDA. Perhaps they can't do until IND is filed?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 24, 2016 9:08:42 GMT -5
Interesting the way the health care system gouges American consumers: "After insurance company discounts, a package of two EpiPens costs about $415, DRX says. By comparison, in France, where Meda sells the drug, two EpiPens cost about $85." Thinking about it, there may be lessons for MNKD. There are other auto-injectors available and some look superior to epipen: autoinjector marketYet Mylan allegedly controls 95% of the auto-injector market and is able to raise prices regularly. How do they get away with that? Why aren't any of those other companies' products able to gain market share? perception. Great value pasta is significantly cheaper than Barilla pasta
|
|
|
Post by kc on Aug 24, 2016 9:20:31 GMT -5
|
|